Yosra Vaez-Gharamaleki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yosra Vaez-Gharamaleki has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad-Salar Hosseini
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
9 shared publications - Mohammad Amin Akbarzadeh
Medical Philosophy and History Research Center, Tabriz University of Medical Sciences
7 shared publications - Farid Jahanshahlou
Research Center for IntegrativeMedicine in Aging, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Hossein Jabbari Beyrami
Health Services Management Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Alireza Ghaffari
Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Alireza Rahimi-Mamaghani
Clinical Research Development Unit of Tabriz Valiasr Hospital, University of Medical Sciences , Tabriz
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (11) , 14934-14935
The rising burden of ovarian cancer in the Middle East and North Africa and the need for immediate measures
- 14 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (11) , 14934-14935
Open AccessThe rising burden of ovarian cancer in the Middle East and North Africa and the need for immediate measures
- 9 July 2026
- Published by Springer Nature
- p. 1821-1828
Disability-Inclusive Palliative Care
- 1 January 2026
- Published by Maad Rayan Publishing Company in International Journal of Aging
- Vol. 4, e9147
Incidence, Mortality, and Future Burden of Gastrointestinal Cancers Among Older Adults in Iran: A Population-based Analysis and Projection for 2050
Objectives: To evaluate the incidence and mortality of gastrointestinal cancers among older adults in Iran and to project their future burden through 2050. Design: Population-based study. Setting: National-level epidemiological analysis in Iran using data from the Global Cancer Observatory database. Participants: Individuals aged 60 years and older diagnosed with major gastrointestinal malignancies, including esophageal, stomach, colorectal, anal, liver, gallbladder, and pancreatic cancers. Outcome Measures: Estimated numbers of incident cases and deaths, age-standardized incidence and mortality rates (ASIRs and ASMRs), sex-specific distributions, and mortality-to-incidence ratios (MIRs), along with projected incidence and mortality estimates through 2050, were reported. In addition, Spearman’s rank correlation analysis was performed to evaluate the association between incidence and mortality across major gastrointestinal cancer sites. A P-value of less than 0.05 was considered statistically significant. Results: In 2022, a total of 29704 new gastrointestinal cancer cases and 24900 gastrointestinal cancer-related deaths occurred among individuals aged ≥60 years in Iran. The overall ASIR and ASMR were 312.5 and 259.3 per 100000 population, respectively. Men accounted for 62.23% of incident cases and 59.94% of deaths. Stomach cancer was the most common gastrointestinal malignancy. Liver, esophageal, and pancreatic cancers demonstrated disproportionately high mortality relative to incidence. By 2050, the number of new gastrointestinal cancer cases among older adults is projected to increase to over 100000 cases, while gastrointestinal cancer-related deaths are expected to rise to over 92500, with increases of more than 240% and 270%, respectively. Sensitivity analyses showed stable cancer-ranking patterns and consistent MIR estimates across alternative projection scenarios. A very strong positive correlation was observed between ASIRs and ASMRs across gastrointestinal cancer sites among older adults in Iran, indicating that gastrointestinal cancers with higher incidence account for correspondingly higher mortality burden. Conclusions: The burden of gastrointestinal cancers is rapidly increasing among older adults in Iran, and the projected rise of incidence and mortality by 2050 highlights the urgent need for comprehensive prevention strategies, early detection programs, and expansion of geriatric oncology services to address the growing cancer burden in the aging Iranian population.
- 1 January 2026
- Published by Maad Rayan Publishing Company in International Journal of Aging
- Vol. 4, e9147
Incidence, Mortality, and Future Burden of Gastrointestinal Cancers Among Older Adults in Iran: A Population-based Analysis and Projection for 2050
Objectives: To evaluate the incidence and mortality of gastrointestinal cancers among older adults in Iran and to project their future burden through 2050. Design: Population-based study. Setting: National-level epidemiological analysis in Iran using data from the Global Cancer Observatory database. Participants: Individuals aged 60 years and older diagnosed with major gastrointestinal malignancies, including esophageal, stomach, colorectal, anal, liver, gallbladder, and pancreatic cancers. Outcome Measures: Estimated numbers of incident cases and deaths, age-standardized incidence and mortality rates (ASIRs and ASMRs), sex-specific distributions, and mortality-to-incidence ratios (MIRs), along with projected incidence and mortality estimates through 2050, were reported. In addition, Spearman’s rank correlation analysis was performed to evaluate the association between incidence and mortality across major gastrointestinal cancer sites. A P-value of less than 0.05 was considered statistically significant. Results: In 2022, a total of 29704 new gastrointestinal cancer cases and 24900 gastrointestinal cancer-related deaths occurred among individuals aged ≥60 years in Iran. The overall ASIR and ASMR were 312.5 and 259.3 per 100000 population, respectively. Men accounted for 62.23% of incident cases and 59.94% of deaths. Stomach cancer was the most common gastrointestinal malignancy. Liver, esophageal, and pancreatic cancers demonstrated disproportionately high mortality relative to incidence. By 2050, the number of new gastrointestinal cancer cases among older adults is projected to increase to over 100000 cases, while gastrointestinal cancer-related deaths are expected to rise to over 92500, with increases of more than 240% and 270%, respectively. Sensitivity analyses showed stable cancer-ranking patterns and consistent MIR estimates across alternative projection scenarios. A very strong positive correlation was observed between ASIRs and ASMRs across gastrointestinal cancer sites among older adults in Iran, indicating that gastrointestinal cancers with higher incidence account for correspondingly higher mortality burden. Conclusions: The burden of gastrointestinal cancers is rapidly increasing among older adults in Iran, and the projected rise of incidence and mortality by 2050 highlights the urgent need for comprehensive prevention strategies, early detection programs, and expansion of geriatric oncology services to address the growing cancer burden in the aging Iranian population.
- 3 October 2025
- Published by IGI Global Scientific Publishing
- p. 331-370
Palliative and Supportive Care for Advanced Non-Small Cell Lung Cancer
The majority of non-small cell lung cancer (NSCLC) patients are diagnosed at advanced stages, where curative treatments may no longer result in optimal outcomes, and the quality of life is limited by disease- or treatment-related adverse events. This chapter explores the principles and practices of palliative and supportive care in NSCLC, emphasizing the importance of early integration into standard oncology care. Core discussed topics include clinical symptom management (including pain, dyspnea, fatigue, cough, nausea/vomiting, anorexia, and cachexia), psychological and psychosocial support (including psychological distress, caregiver burden, financial toxicity, cultural considerations, and spiritual suffering), management of disease- and treatment-related complications (including coagulopathy, malignant pleural effusion, superior vena cava syndrome, spinal cord compression, hypercalcemia, and hematologic, neurological, and dermatologic complications), ethical decision-making, and the role of a multidisciplinary palliative care team.
- 3 October 2025
- Published by IGI Global Scientific Publishing
- p. 331-370
Palliative and Supportive Care for Advanced Non-Small Cell Lung Cancer
The majority of non-small cell lung cancer (NSCLC) patients are diagnosed at advanced stages, where curative treatments may no longer result in optimal outcomes, and the quality of life is limited by disease- or treatment-related adverse events. This chapter explores the principles and practices of palliative and supportive care in NSCLC, emphasizing the importance of early integration into standard oncology care. Core discussed topics include clinical symptom management (including pain, dyspnea, fatigue, cough, nausea/vomiting, anorexia, and cachexia), psychological and psychosocial support (including psychological distress, caregiver burden, financial toxicity, cultural considerations, and spiritual suffering), management of disease- and treatment-related complications (including coagulopathy, malignant pleural effusion, superior vena cava syndrome, spinal cord compression, hypercalcemia, and hematologic, neurological, and dermatologic complications), ethical decision-making, and the role of a multidisciplinary palliative care team.
- Open Access
- 8 May 2025
- Published by Elsevier in ESMO Rare Cancers
- Vol. 3
Mirdametinib approval for neurofibromatosis type 1 with inoperable plexiform neurofibromas: the journey of MEK inhibitors
- 8 May 2025
- Published by Elsevier in ESMO Rare Cancers
- Vol. 3
Open AccessMirdametinib approval for neurofibromatosis type 1 with inoperable plexiform neurofibromas: the journey of MEK inhibitors
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2400246
PLSKB: An Interactive Knowledge Base to Support Diagnosis, Treatment, and Screening of Lynch Syndrome on the Basis of Precision Oncology
PURPOSE: Understanding the genetic heterogeneity of Lynch syndrome (LS) cancers has led to significant scientific advancements. However, these findings are widely dispersed across various resources, making it difficult for clinicians and researchers to stay informed. Furthermore, the uneven quality of studies and the lack of effective translation of knowledge into clinical practice create challenges in delivering optimal patient care. To address these issues, we developed and launched the Precision Lynch Syndrome Knowledge Base (PLSKB), a specialized, interactive web-based platform that consolidates comprehensive information on LS. METHODS: To create the PLSKB, we conducted an extensive literature review and gathered data from reliable sources. Through an extensive literature review and survey of other reliable sources, we have extracted prominent and relevant content with a high level of accuracy, transparency, and detailed provenance. To enhance usability, we implemented an evidence-leveling framework, categorizing studies on the basis of the type of research, reliability, and applicability to clinical care. The platform is designed to be dynamic, with updates performed monthly to incorporate the latest research. RESULTS: The PLSKB integrates a broad spectrum of data related to LS, including biomarkers, cancer types, screening and prevention strategies, diagnostic methods, and therapeutics options. This centralized resource is intended to support clinicians and researchers in making evidence-based decisions throughout surveillance and care processes. Its interactive design and frequent updates ensure that users have access to the most current and relevant findings. CONCLUSION: The PLSKB bridges the gap between research and clinical practice by offering a reliable, up-to-date repository of evidence-based information. This tool empowers clinicians and researchers to deliver precision care and advance research for LS and related conditions, ultimately improving patient outcomes.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2400246
PLSKB: An Interactive Knowledge Base to Support Diagnosis, Treatment, and Screening of Lynch Syndrome on the Basis of Precision Oncology
PURPOSE: Understanding the genetic heterogeneity of Lynch syndrome (LS) cancers has led to significant scientific advancements. However, these findings are widely dispersed across various resources, making it difficult for clinicians and researchers to stay informed. Furthermore, the uneven quality of studies and the lack of effective translation of knowledge into clinical practice create challenges in delivering optimal patient care. To address these issues, we developed and launched the Precision Lynch Syndrome Knowledge Base (PLSKB), a specialized, interactive web-based platform that consolidates comprehensive information on LS. METHODS: To create the PLSKB, we conducted an extensive literature review and gathered data from reliable sources. Through an extensive literature review and survey of other reliable sources, we have extracted prominent and relevant content with a high level of accuracy, transparency, and detailed provenance. To enhance usability, we implemented an evidence-leveling framework, categorizing studies on the basis of the type of research, reliability, and applicability to clinical care. The platform is designed to be dynamic, with updates performed monthly to incorporate the latest research. RESULTS: The PLSKB integrates a broad spectrum of data related to LS, including biomarkers, cancer types, screening and prevention strategies, diagnostic methods, and therapeutics options. This centralized resource is intended to support clinicians and researchers in making evidence-based decisions throughout surveillance and care processes. Its interactive design and frequent updates ensure that users have access to the most current and relevant findings. CONCLUSION: The PLSKB bridges the gap between research and clinical practice by offering a reliable, up-to-date repository of evidence-based information. This tool empowers clinicians and researchers to deliver precision care and advance research for LS and related conditions, ultimately improving patient outcomes.
- Open Access
- 21 February 2024
- Published by Maad Rayan Publishing Company in International Journal of Drug Research in Clinics
- Vol. 2 (1) , e28
Long-Term Outcomes and Potential Late-Onset Side Effects of Combination Therapy in Older Immunocompromised Patients Treated for COVID-19
The COVID-19 pandemic has affected global health, particularly vulnerable populations such as the aged and immunocompromised individuals who face heightened risks due to age-related physiological changes and comorbidities. Recent cohort studies have indicated that older adults constitute a substantial proportion of hospitalizations and mortality associated with COVID-19, due to decreased physiological reserves and immunosenescence. Combination therapy has been proposed as a primary therapeutic strategy for managing severe COVID-19 in immunocompromised patients, typically involving multiple pharmacological agents, including antivirals, immunomodulatory agents, and supportive care. Compared to monotherapy regimens, recent studies have demonstrated that combination therapies lead to reduced viral load, improved clinical outcomes, and lower mortality rates. Meanwhile, the long-term outcomes of these combination therapies, along with specific details of the post-acute sequelae of COVID-19 (PASC), also referred to as long COVID, in older immunocompromised patients remain under investigation. This review aims to explore these aspects in greater detail, investigating the efficacy of combination therapies in treating COVID-19 among older immunocompromised patients, with a particular focus on their long-term implications.
- 21 February 2024
- Published by Maad Rayan Publishing Company in International Journal of Drug Research in Clinics
- Vol. 2 (1) , e28
Open AccessLong-Term Outcomes and Potential Late-Onset Side Effects of Combination Therapy in Older Immunocompromised Patients Treated for COVID-19
The COVID-19 pandemic has affected global health, particularly vulnerable populations such as the aged and immunocompromised individuals who face heightened risks due to age-related physiological changes and comorbidities. Recent cohort studies have indicated that older adults constitute a substantial proportion of hospitalizations and mortality associated with COVID-19, due to decreased physiological reserves and immunosenescence. Combination therapy has been proposed as a primary therapeutic strategy for managing severe COVID-19 in immunocompromised patients, typically involving multiple pharmacological agents, including antivirals, immunomodulatory agents, and supportive care. Compared to monotherapy regimens, recent studies have demonstrated that combination therapies lead to reduced viral load, improved clinical outcomes, and lower mortality rates. Meanwhile, the long-term outcomes of these combination therapies, along with specific details of the post-acute sequelae of COVID-19 (PASC), also referred to as long COVID, in older immunocompromised patients remain under investigation. This review aims to explore these aspects in greater detail, investigating the efficacy of combination therapies in treating COVID-19 among older immunocompromised patients, with a particular focus on their long-term implications.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 15
Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 15
Open AccessMechanisms of resistance to histone deacetylase inhibitors in acute leukemia
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (8) , e20240322
Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis
Since the beginning of the COVID-19 pandemic, complications of this disease among vulnerable populations have been a primary concern. Cancer patients are among the most vulnerable groups of patients owing to the compromised immune system and weakened overall health status1 1 Akbarzadeh MA, Hosseini MS. Implications for cancer care in Iran during COVID-19 pandemic. Radiother Oncol. 2020;148:148:211-2. https://doi.org/10.1016/j.radonc.2020.04.041 https://doi.org/10.1016/j.radonc.2020.04... .
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (8) , e20240322
Open AccessOutcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis
Since the beginning of the COVID-19 pandemic, complications of this disease among vulnerable populations have been a primary concern. Cancer patients are among the most vulnerable groups of patients owing to the compromised immune system and weakened overall health status1 1 Akbarzadeh MA, Hosseini MS. Implications for cancer care in Iran during COVID-19 pandemic. Radiother Oncol. 2020;148:148:211-2. https://doi.org/10.1016/j.radonc.2020.04.041 https://doi.org/10.1016/j.radonc.2020.04... .